Market Intelligence, Clinical Progress, and High-Purity Reagents for IGF Axis, Apoptosis, Diabetes, and Inflammatory Indications.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TMEM219 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TMEM219 ECD-Fc Fusion Protein / Mutant Protein High purity (>95%), Endotoxin <1 EU/µg, Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View TMEM219 Products |
| Gene Delivery | TMEM219 Full-Length ORF / Lentivirus Full-length ORF for stable cell lines preserving native single-pass membrane topology. |
View TMEM219 Products |
| Benchmark Ab | Anti-TMEM219 Recombinant Antibody (Biosimilar Sequence) Sequence-defined monoclonal positive control for binding and blockade assays. |
View TMEM219 Products |
| Validator | TMEM219 siRNA Set For knockdown verification and assay specificity controls. |
View TMEM219 Products |
| Related Target A | IGF1R Coreceptor in IGF signaling axis; synergy or resistance node in TMEM219-mediated apoptosis. |
View IGF1R Products |
| Related Target B | IGFBP3 Endogenous ligand for TMEM219; interaction drives apoptosis. |
View IGFBP3 Products |
| Related Target C | CASP8 Downstream effector of TMEM219-mediated cell death. |
View CASP8 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native glycosylation required for ligand (IGFBP-3) binding fidelity | HEK293-expressed ECD-Fc with verified mammalian glycosylation pattern and >95% purity |
| Full-length conformation for internalization and apoptosis studies | Premade lentivirus particles for stable, high-expression cell lines preserving native topology |
| Cross-species evaluation (human/mouse/cyno) for preclinical translation | Ortholog ECD proteins available with sequence-verified identity and endotoxin control |
| Off-target liability within IGF receptor superfamily | Homolog panel (IGF1R, IGF2R) for stringent counter-screening by SPR/BLI |
| Assay specificity and false-positive mitigation | siRNA included for genetic knockdown confirmation of target engagement |
| Lack of assay controls (benchmark antibodies) | Clinical benchmark antibodies (biosimilars) included for assay calibration |
Live TMEM219 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TMEM219-targeted therapeutics is intensifying across two major domains: oncology and metabolic/inflammatory disease. In oncology, TMEM219 acts as an apoptotic receptor for IGFBP-3, offering a distinct mechanism from canonical IGF1R blockade for solid tumors (prostate, breast). In metabolic and inflammatory conditions, neutralizing TMEM219 protects beta cells from apoptosis in diabetes, reduces airway remodeling in asthma, and mitigates acute kidney injury. First-generation programs (monoclonal antibodies, small molecules, and gene therapies) remain predominantly preclinical or early-stage. The next wave will focus on differentiated modalities such as antibody-drug conjugates (ADCs), ligand-mimetic biologics, and combination therapies with immune checkpoint inhibitors or regenerative medicine. Precise epitope selection and cross-reactivity management with IGF1R, IGF2R, and other death receptors will be critical for success.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus/Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Apoptosis Induction) | Discovery-stage biotech and academic programs | Solid Tumors (Prostate, Breast) | Binding & Blockade Assay (Need high-purity ECD-Fc and reference antibody) |
| Monoclonal Antibody (Blocking/Neutralizing) | Emerging biotech / academic spin-offs | Diabetes (Beta-cell preservation), Asthma | Blocking Assay (Need high-purity ECD-Fc and IGFBP3) |
| Antibody-Drug Conjugate (ADC) / Payload Delivery | Emerging pipeline candidates | IGF1R-Refractory Solid Tumors | Internalization Assay (Need full-length lentivirus stable cell line) |
| Recombinant Ligand / Peptide (IGFBP-3 mimetic) | Metabolic / oncologic applications | Metabolic & Oncologic | Ligand Competition SPR (Need native glycosylated ECD) |
| Small Molecule | Mid-size pharma | Acute Kidney Injury, Tissue Inflammation | Selectivity Assay (Need structural fidelity / Sequence Verified proteins) |
| Gene Therapy / RNAi | Preclinical innovators | Organ preservation | Knockdown Verification (Need verified siRNA and Lentivirus cell lines) |